Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.

Journal: Advances in clinical and experimental medicine : official organ Wroclaw Medical University

PMID: 26771971

Abstract

BACKGROUND: Rivaroxaban (Xarelto) does not require routine coagulation monitoring; however, in certain clinical situations (overdose, drug accumulation, urgent surgery) measurement of its plasma concentration is highly recommended. Currently, there is no single hemostasis test that shows a direct correlation between rivaroxaban plasma levels and anticoagulant efficacy.

Authors

Krzysztof Chojnowski

Department of Hematology, Medical University of Lodz, Poland.
Tomasz Górski

Department of Hematology, Medical University of Lodz, Poland.
Marta Robak

Department of Hematology, Medical University of Lodz, Poland.
Jacek Treliński

Department of Hematology, Medical University of Lodz, Poland.

Keywords

Blood Coagulation Case-Control Studies Drug Monitoring Factor Xa Inhibitors Humans Partial Thromboplastin Time Predictive Value of Tests Prothrombin Time Rivaroxaban Thrombelastography Time Factors Treatment Outcome Venous Thromboembolism

External Resources

View on PubMed Access via DOI PubMed (26771971)

Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.

Abstract

Authors

Keywords

External Resources

Popular Topics

Recent Journals